Article

Medicare Reform Vote Falls Short-July 2008

HR 6331 narrowly fails to get the support it needs in the Senate.

Although the Medicare Improvements for Patients and Providers Act of 2008 (HR 6331) passed the House with an overwhelming majority, the landmark legislation that provides pharmacy-friendly provisions failed to get the 60 Senate votes it needed on June 26. Pharmacy leaders are hopeful that lawmakers can quickly resolve the issues and pass the bill in the coming weeks.

Despite the setback, pharmacy groups feel they won a key victory on June 24 when the House passed HR 6331 with a vote of 355 to 59. The party breakdown was 226 Democrats and 129 Republicans in favor and 59 Republicans against.

Washington

Bruce Roberts, RPh, executive vice president and chief executive officer of the National Community Pharmacists Association, said the association was disappointed by the vote and thanked all senators who voted for the bill. “Unfortunately, our issues, which enjoy overwhelming bipartisan support, got wrapped up in a contentious debate unrelated to pharmacy.” Nevertheless, he said, “this often happens in . We look forward to working with all our friends on Capitol Hill in the coming weeks to ensure that legislation protecting the public’s access to life-saving prescription drugs and related counsel become law.”

The National Association of Chain Drug Stores agreed. “The bill garnered bipartisan support in both the Senate and the House, reflecting the bill’s importance to health care and the nation’s economy,” said Steven C. Anderson, IOM, CAE, president and chief executive officer of the association. He said the group will continue to fight for pharmacy provisions in HR 6331.

The pharmacy provisions in the bill include postponing, until October 1, 2009, implementation of the new Average Manufacturer Price—based pharmacy payment plan for generics dispensed under Medicaid; accelerating faster payment of Medicare Part D drug claims; and delaying the implementation of the competitive billing program for durable medical equipment, prosthetics, orthotics, and supplies under Medicare Part B.

Related Videos
Ladan Zand, MD: Evaluating Obinutuzumab in Primary FSGS and Further Research
ADORING Trial Open-Label Extension: Tapinarof Cream 1% Results in Atopic Dermatitis
Kishore Iyer, MD , MBBS | Credit: Kishore Iyer on LinkedIn
Evan Dellon, MD, MPH | Credit: UNC Chapel Hill
Marlyn Mayo, MD | Credit: ACG
Kishore Iyer, MD, MBBS | Credit: Kishore Iyer on LinkedIn
Linda Stein Gold, MD: Discussing New Phase 3b Data on Lebrikizumab for Atopic Dermatitis
Bruce Sands, MD | Credit: Alimentiv
Andrea Murina, MD: Drug Pipeline for Hidradenitis Suppurativa
Quan Dong Nguyen, MD: Phase 2 Neptune Trial Advances Brepocitnib for Uveitis | Image Credit: Stanford University
© 2024 MJH Life Sciences

All rights reserved.